Episodes of Raynaud's phenomenon, a common feature of systemic sclerosis (SSc, also known as scleroderma), were more severe not only at low temperatures, as one would expect, but also during summertime heat, a multinational study found.
Dr. John Cush RheumNow
1 year 11 months ago
Life Essential 8 (LE8) score studied in RA & SLE was neg. corrlated w/ DAS28 (r −0.96) & SLEDAI (r − 0.81) & assoc w/ 10 yr survival. LE8 score: smoking, sleep, physical activity, diet, BMI, non-HDL, BP, fasting glucose, & HgbA1c. https://t.co/DCpWKzmt80 https://t.co/eKqqEO1F65
Dr. John Cush RheumNow
1 year 11 months ago
Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders https://t.co/TWx62EhRBl https://t.co/6uhoRowg3n
Dr. John Cush RheumNow
1 year 11 months ago
Retrospective observational study of 96 stable #SLE pts compared maintenance on HCQ vs belimumab. There were no significant differences in Flare rate (18% HCQ vs 8.3% BLM; p=0.47), damage index increase, SLEDAI, Pred dose or adverse events https://t.co/sVPMugSHn3 https://t.co/6bdel6Kvs9
Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility.
Dr. John Cush RheumNow
1 year 11 months ago
Consumption of Alcohol and the Risk of Gout
Alcohol is a risk factor for gout and flares. While the inciting potential differs among alcohol types, are these differences sex specific?
https://t.co/CzE9ZSEN9f https://t.co/e4WBSBlNEo
A national cohort study shows that continuous use of hydroxychloroquine (HCQ) protects agains cardiovascular (CV) events in patients with systemic lupus erythematosus (SLE).
Dr. John Cush RheumNow
1 year 11 months ago
Scleroderma skin findings in pts w/ skin of colour (SOC) - Raynauds was common but SOC pts had fewer hallmark Sxs: telangiectasias, calcinosis, digital swelling (complicating Dx). SOC had more severe pulmonary Dz & increased mortality, Atypical skin findings… https://t.co/8XkelxqvYE https://t.co/JOw8OSNjzw
Dr. John Cush RheumNow
1 year 11 months ago
It takes >3-4 weeks of steroids (@ any dose >5 mg pred/d) to pose risk of adrenal insufficiency – Hence, Endocrine Society Guideline says short-term glucocorticoid therapy of <3-4 wks, irrespective of dose, DOES NOT require GC tapering https://t.co/o7tz1Am9pe https://t.co/CndfCYRApj
Dr. John Cush RheumNow
1 year 11 months ago
Birth Control Use in Lupus
Published guidelines on lupus mgmt urge that female patients plan and prepare carefully for pregnancy, and use contraceptives when it's not intended -- but these reco’s are rarely followed, a registry study suggested.
https://t.co/81mQbp5Sib https://t.co/NJmwxvtR44
Dr. John Cush RheumNow
1 year 11 months ago
ANA's over time may be more dynamic than previously accepted. SLE & ANA+associated Dz tend to have higher titers, esp. higher in early disease, but decrease over time https://t.co/caUazl9U6S https://t.co/jBglFBJ886
Dr. John Cush RheumNow
1 year 11 months ago
Renal Impairment in Rheumatoid Arthritis
Patients with highly active rheumatoid arthritis (RA) experienced faster declines in kidney function than those whose disease was under better control, analysis of a large registry indicated.
https://t.co/WaUDtJCitG https://t.co/RmPPLsihAG
Dr. John Cush RheumNow
1 year 11 months ago
ACR Backs FDA Rule Change on Interchangeable Biosimilars
The ACR submitted comments to the FDA supporting their proposal to update the approval process for biosimilars’ interchangeability status.
https://t.co/YD11qZJxIr https://t.co/tVij0ebwz4
Dr. John Cush RheumNow
1 year 11 months ago
ANCA-associated vasculitis analysis of 6 European registries, 3868 pts (2434 GPA, 1434 MPA), age ~57 yrs. Identified 5 clusters: 3 w/ renal dz a) variable ANCA, Hi CRP & Cr; b) MPO+; c) PR3+ & 2 extrarenal 1) PR3+ multisystem; 2) ENT w/ low CRP. Clusters better predicted outcomes… https://t.co/XZcSZ6lGjH https://t.co/yEg64YGTrA
Dr. John Cush RheumNow
1 year 11 months ago
Myositis (IIM) pts w/ ILD have higher mortality. Study of IIM (n 190) vs myositis-mimics (414) shows ILD risk incr by myositis-specific antibody (MSA) 6 fold; Ro-52 8 fold; or 20 fold with dual positivity (MSA + Ro-52 antibodies) https://t.co/oLFflVjzOb https://t.co/uzqpfBP28M

